Review of immunotherapy innovations for triple-negative breast cancer survival
New Hope for Tough-to-Treat Breast Cancer
This narrative review examines immunotherapy innovations, including immune checkpoint inhibitors and combination strategies, for patients wi…
This approach may change how doctors treat one of the hardest forms of breast cancer.
Systematic review examines immune checkpoint inhibitors, innate immunity, and immune-related adverse events in cancer patients.
A review suggests innate immunity plays a key role in cancer drug side effects.
This systematic review evaluated immune checkpoint inhibitors (ICIs) in patients with cancer, focusing on immune-related adverse events (irA…
Cancer drugs that help fight tumors can also cause serious inflammation, and new research shows the body's first line of defense plays a key…
Systematic review examines immunotherapy resistance mechanisms and strategies in hepatocellular carcinoma patients.
Why Liver Cancer Stops Responding to Immunotherapy — and What Could Change That
This systematic review evaluated drug resistance mechanisms and strategies to overcome resistance in patients with hepatocellular carcinoma …
Understanding why liver cancer learns to dodge the immune system's attack is the first step toward treatments that can keep working long-ter…
PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC
Does combining these lung cancer drugs extend life, or just delay disease growth?
A meta-analysis of 2,787 patients with advanced or metastatic NSCLC found that combining PD-1/PD-L1 inhibitors with multi-targeted anti-angi…
Combining lung cancer drugs slows disease growth but offers no clear survival benefit for patients with advanced non-small cell lung cancer.